mTOR, cancer and transplantation

Area of Science:

• Molecular Biology
• Immunology
• Oncology
• Transplantation Medicine

Background:

• The mammalian target of rapamycin (mTOR) pathway is a key regulator of cellular processes, including growth, proliferation, and survival.
• Dysregulation of the mTOR pathway is implicated in both cancer progression and immune responses, making it a critical target in organ transplantation.

Purpose of the Study:

• To review the latest molecular developments in mTOR signaling.
• To explore the potential of pharmacologic mTOR intervention in managing transplant recipients.
• To balance long-term antidonor immune responses and the risk of malignancy.

Main Methods:

• Literature review of current research on mTOR signaling pathways.
• Analysis of the role of mTOR in T cell IL-2 signaling and alloimmune reactivity.
• Examination of mTOR's involvement in neoplastic cell activation and cancer development.

Main Results:

• The mTOR pathway controls vital cellular functions, influencing immune reactivity and cancer progression.
• mTOR activity blockade can inhibit T cell signaling, impacting alloimmune responses.
• Constitutive activation of mTOR is frequently observed in cancer cells.

Conclusions:

• A comprehensive understanding of mTOR signaling is essential for organ transplant recipients.
• Pharmacologic modulation of mTOR may offer a strategy to mitigate risks of allograft rejection and cancer development.
• Targeting mTOR presents a potential therapeutic approach to improve long-term outcomes in transplantation.